
12 High-Yield Stocks From Deutsche Bank's Best Long Ideas
Last month's global market selloff following the Brexit decision was a doozy for investors who had to endure extreme market volatility only to be followed up by three days of rallying by stocks.
Still, the market volatility opened up lots of opportunity to buy stocks that were beaten down from worries over Brexit. Following the selloff, Deutsche Bank issued a report on June 28 with 42 best long ideas from its equity analysts with the most compelling "risk/reward from current levels." Granted, the list was compiled following two days where the Dow Jones Industrial Average had triple-digit selloffs (only to be followed by a three-day rally).
TheStreet culled the list and found 12 stocks with dividend yields above 2.5% and strong fundamental stories. We included a snippet of why Deutsche Bank analysts like each of these stocks.



![June Return: 2.9% DB Price Target: $160 Dividend Yield: 3.52%"We like [Boeing ] as the cash flow growth and deployment story is underappreciated and everyone is short the stock and few are long," wrote analyst Myles Walton. "We see execution risk for the name at near-decade low and see the 787 having far more profit potential than the bears would ever believe (margins have expanded from -48% to 1% over the last 8 quarters and should be at 10%+ cash gross margins by 4Q16)."](https://www.thestreet.com/.image/c_fill%2Ccs_srgb%2Cg_face%2Ch_80%2Cq_auto:good%2Cw_80/MTY4NjQ4NDA1MDAwOTg4NTY3/boeing.png)





![June Return: -0.81% DB Price Target: $49 Dividend Yield: 2.77%"As we look out to the end of 2016, we believe some of the overhands for [Abbott Labs ] should start to life (i.e. visibility on Alere, product approvals for St. Jude) and as such the stock should appreciate," wrote analyst Kristen Stewart. "In 2017, we believe ABT shares could be a top performer in the space."](https://www.thestreet.com/.image/c_fill%2Ccs_srgb%2Cg_face%2Ch_80%2Cq_auto:good%2Cw_80/MTY4NjQ4NDA1MDAyMTY4MjE1/abbott-laboratories.png)

![June Return: 4.9% DB Price Target: $98 Dividend Yield: 2.74%"Our Buy rating on [Eli Lilly ] is based on continued momentum in its diabetes franchise, under-the-radar immunology franchise opportunities ... an underappreciated animal health franchise, potential to be first to market with an Alzheimer's drug and continued momentum in diabetes franchise. Solanezumab Phase 3 readout could be a positive catalyst," wrote analyst Gregg Gilbert.](https://www.thestreet.com/.image/c_fill%2Ccs_srgb%2Cg_face%2Ch_80%2Cq_auto:good%2Cw_80/MTY4NjQ4NDA1MjcwNDcyNTk5/eli-lilly.png)










